328 related articles for article (PubMed ID: 31077356)
41. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.
Maina T; Bergsma H; Kulkarni HR; Mueller D; Charalambidis D; Krenning EP; Nock BA; de Jong M; Baum RP
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):964-973. PubMed ID: 26631238
[TBL] [Abstract][Full Text] [Related]
42. Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with
Yook S; Cai Z; Jeong JJ; Lu Y; Winnik MA; Pignol JP; Reilly RM
Mol Pharm; 2020 Apr; 17(4):1226-1236. PubMed ID: 32022567
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice.
Johnson CV; Shelton T; Smith CJ; Ma L; Perry MC; Volkert WA; Hoffman TJ
Cancer Biother Radiopharm; 2006 Apr; 21(2):155-66. PubMed ID: 16706636
[TBL] [Abstract][Full Text] [Related]
44. The GRPR Antagonist [
Abouzayed A; Borin J; Lundmark F; Rybina A; Hober S; Zelchan R; Tolmachev V; Chernov V; Orlova A
Diagnostics (Basel); 2023 May; 13(9):. PubMed ID: 37175001
[TBL] [Abstract][Full Text] [Related]
45. PET Using a GRPR Antagonist
Zhang J; Niu G; Fan X; Lang L; Hou G; Chen L; Wu H; Zhu Z; Li F; Chen X
J Nucl Med; 2018 Jun; 59(6):922-928. PubMed ID: 29123014
[TBL] [Abstract][Full Text] [Related]
46. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours.
Zhang H; Schuhmacher J; Waser B; Wild D; Eisenhut M; Reubi JC; Maecke HR
Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1198-208. PubMed ID: 17262215
[TBL] [Abstract][Full Text] [Related]
47. Side-by-side comparison of the two widely studied GRPR radiotracers, radiolabeled NeoB and RM2, in a preclinical setting.
Damiana TST; Paraïso P; de Ridder C; Stuurman D; Seimbille Y; Dalm SU
Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3851-3861. PubMed ID: 37584725
[TBL] [Abstract][Full Text] [Related]
48. Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules.
Westerlund K; Honarvar H; Norrström E; Strand J; Mitran B; Orlova A; Eriksson Karlström A; Tolmachev V
Mol Pharm; 2016 May; 13(5):1668-78. PubMed ID: 27010700
[TBL] [Abstract][Full Text] [Related]
49. Comparative evaluation of the new GRPR-antagonist
Lymperis E; Kaloudi A; Kanellopoulos P; Krenning EP; de Jong M; Maina T; Nock BA
J Labelled Comp Radiopharm; 2019 Aug; 62(10):646-655. PubMed ID: 30963606
[TBL] [Abstract][Full Text] [Related]
50. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
51. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
[TBL] [Abstract][Full Text] [Related]
52. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy.
Ruigrok EAM; van Vliet N; Dalm SU; de Blois E; van Gent DC; Haeck J; de Ridder C; Stuurman D; Konijnenberg MW; van Weerden WM; de Jong M; Nonnekens J
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1339-1350. PubMed ID: 33094433
[TBL] [Abstract][Full Text] [Related]
53. GRPR-selective PET imaging of prostate cancer using [(18)F]-lanthionine-bombesin analogs.
Carlucci G; Kuipers A; Ananias HJ; de Paula Faria D; Dierckx RA; Helfrich W; Rink R; Moll GN; de Jong IJ; Elsinga PH
Peptides; 2015 May; 67():45-54. PubMed ID: 25797109
[TBL] [Abstract][Full Text] [Related]
54. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression.
Maddalena ME; Fox J; Chen J; Feng W; Cagnolini A; Linder KE; Tweedle MF; Nunn AD; Lantry LE
J Nucl Med; 2009 Dec; 50(12):2017-24. PubMed ID: 19910427
[TBL] [Abstract][Full Text] [Related]
55. Preclinical evaluation of a novel ¹¹¹In-labeled bombesin homodimer for improved imaging of GRPR-positive prostate cancer.
Carlucci G; Ananias HJ; Yu Z; Hoving HD; Helfrich W; Dierckx RA; Liu S; de Jong IJ; Elsinga PH
Mol Pharm; 2013 May; 10(5):1716-24. PubMed ID: 23590837
[TBL] [Abstract][Full Text] [Related]
56. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors.
Abiraj K; Mansi R; Tamma ML; Fani M; Forrer F; Nicolas G; Cescato R; Reubi JC; Maecke HR
J Nucl Med; 2011 Dec; 52(12):1970-8. PubMed ID: 22080443
[TBL] [Abstract][Full Text] [Related]
57. Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy.
Garcia-Prada CD; Carmes L; Atis S; Parach A; Bertolet A; Jarlier M; Poty S; Garcia DS; Shin WG; Du Manoir S; Schuemann J; Tillement O; Lux F; Constanzo J; Pouget JP
J Nucl Med; 2023 Dec; 64(12):1956-1964. PubMed ID: 37857502
[TBL] [Abstract][Full Text] [Related]
58. In Vivo Stabilized SB3, an Attractive GRPR Antagonist, for Pre- and Intra-Operative Imaging for Prostate Cancer.
Bakker IL; van Tiel ST; Haeck J; Doeswijk GN; de Blois E; Segbers M; Maina T; Nock BA; de Jong M; Dalm SU
Mol Imaging Biol; 2018 Dec; 20(6):973-983. PubMed ID: 29556947
[TBL] [Abstract][Full Text] [Related]
59. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
[TBL] [Abstract][Full Text] [Related]
60. Targeted antisense radiotherapy and dose fractionation using a (177)Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate.
Liu D; Balkin ER; Jia F; Ruthengael VC; Smith CJ; Lewis MR
Nucl Med Biol; 2015 Sep; 42(9):704-10. PubMed ID: 26081917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
